Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278952 · ClinicalTrials.gov registry record
Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 50
- Enrollment target
NCT02278952 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 50 participants.
The verdict
NCT02278952 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 50 participants
- Enrollment target
Study Summary
This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The assay measures mean residual expression (MRE) of genes downstream of nuclear factor of activated T cells (NFAT), a transcription factor regulated by tacrolimus. The investigators will assess whether MRE levels identify subjects at risk for rejection (insufficient immunosuppression) or infection (excessive immunosuppression).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278952
The ClinicalTrials.gov registry entry for NCT02278952 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02278952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278952 about?
NCT02278952 is a clinical study titled "Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.". This is a non-interventional cohort study to assess a novel assay to detect excessive or insufficient immunosuppression from the drug tacrolimus in lung transplant recipients. The assay measures mean residual expression (MRE) of genes downstream of nuclear factor of activated T cells (NFAT), a trans...
What is the current status of trial NCT02278952?
This trial is currently completed. The enrollment target is 50 participants. The study started on 2014-12. Estimated completion is 2018-01.
Who is sponsoring clinical trial NCT02278952?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.